Patient Profile and Survival Rate of Breast Cancer Patients with FEC Chemotherapy Regimen at H. Adam Malik Hospital
DOI:
https://doi.org/10.25026/jsk.v5i6.2133Keywords:
Breast cancer, Chemotherapy, Survival rateAbstract
Breast cancer is a prevalent disease that impacts public health worldwide, including Indonesia. There are various chemotherapy regimens that are currently available. One widely utilized chemotherapy regimen for breast cancer is the FEC regimen, which combines 5-fluorouracil, epirubicin, and cyclophosphamide. This study provides a study of patient profiles and survival rates among breast cancer patients undergoing FEC chemotherapy at H. Adam Malik Hospital. The study utilized a descriptive-retrospective approach with data collected from the medical records of patients who underwent FEC therapy at RSUP H. Adam Malik during January-December 2019. A total of 157 patients were administered anthracycline-based treatment, with 54 patients receiving FEC (34.39%). The majority of individuals under the FEC regimen were primarily luminal B (51.75%) and IBC (33.33%). The survival rate for individuals using the FEC chemotherapy regimen was found to be 37.98 months. Additionally, patients with risk factors associated with invasive breast cancer (IBC) exhibited a 1.20-fold increased risk of mortality compared to individuals with other forms of breast cancer. The first-line FEC chemotherapy regimen continues to be a feasible therapeutic option for subtypes of breast cancer, and there is no discernible variation in survival rate observed across these characteristics.
References
H. Sung et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA. Cancer J. Clin., vol. 71, no. 3, pp. 209–249, May 2021, doi: 10.3322/caac.21660.
B. Hardhana, F. Sibuea, and W. Widiantini, Eds., Profil kesehatan indonesia tahun 2019. Jakarta: Kementerian Kesehatan RI, 2020.
H. Thabrany, R. V. Ramadani, E. Adawiyah, B. W. Sasongko, R. Pujisubekti, and C. Jaya, Fakta dan Data Capaian Program Jaminan Kesehatan Nasional 2015-2019, 1st ed. DJSN BPJS, 2021.
J. Anampa, D. Makower, and J. A. Sparano, “Progress in adjuvant chemotherapy for breast cancer: an overview,” BMC Med., vol. 13, p. 195, Aug. 2015, doi: 10.1186/s12916-015-0439-8.
S. ?ukasiewicz, M. Czeczelewski, A. Forma, J. Baj, R. Sitarz, and A. Stanis?awek, “Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review,” Cancers, vol. 13, no. 17, p. 4287, Aug. 2021, doi: 10.3390/cancers13174287.
H. Mardiah, R. N. A. Ginting, H. Rahmadhany, and E. R. D. Sitorus, “Correlation between Age and Body Mass Index (BMI) with Histopathological Features of Breast Cancer Patients in RSUP Haji Adam Malik Medan,” Indones. J. Cancer, vol. 15, no. 2, p. 46, Aug. 2021, doi: 10.33371/ijoc.v15i2.708.
G. Cserni, “Histological type and typing of breast carcinomas and the WHO classification changes over time,” Pathologica, vol. 112, no. 01, pp. 25–41, Mar. 2020, doi: 10.32074/1591-951X-1-20.
W. J. Gradishar et al., “Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology,” J. Natl. Compr. Cancer Netw. JNCCN, vol. 20, no. 6, pp. 691–722, Jun. 2022, doi: 10.6004/jnccn.2022.0030.
A. B. Saptaningsih, U. S. Nikmah, T. Aryandono, I. Dwiprahasto, and J. At Thobari, “Cost-Effectiveness Analysis of Two Chemotherapy Regiments FAC vs. Taxane for Operable Breast Cancer Patients in Indonesia,” Asian Pac. J. Cancer Prev. APJCP, vol. 23, no. 4, pp. 1147–1154, Apr. 2022, doi: 10.31557/APJCP.2022.23.4.1147.
S. M. Lima, R. D. Kehm, and M. B. Terry, “Global breast cancer incidence and mortality trends by region, age-groups, and fertility patterns,” eClinicalMedicine, vol. 38, p. 100985, Aug. 2021, doi: 10.1016/j.eclinm.2021.100985.
P. H. Tan et al., “The 2019 World Health Organization classification of tumours of the breast,” Histopathology, vol. 77, no. 2, pp. 181–185, Aug. 2020, doi: 10.1111/his.14091.
N. Nurmayeni and I. Windarti, “Gambaran Subtipe Molekuler Kanker Payudara di Indonesia,” J. Agromedicine, vol. 9, no. 2, pp. 146–149, 2022.
S. Rahal et al., “Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study,” BMC Cancer, vol. 15, p. 697, Oct. 2015, doi: 10.1186/s12885-015-1746-3.
C. Delbaldo et al., “A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil–epirubicine–cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000),” Eur. J. Cancer, vol. 50, no. 1, pp. 23–30, Jan. 2014, doi: 10.1016/j.ejca.2013.09.023.
G. S. Mannu et al., “Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988-2014: population based observational cohort study,” BMJ, vol. 369, p. m1570, May 2020, doi: 10.1136/bmj.m1570.
J. L. Baker, J. Hegde, C. K. Thompson, M. K. Lee, and M. L. DiNome, “Locoregional Management of Inflammatory Breast Cancer,” Curr. Breast Cancer Rep., vol. 12, no. 4, pp. 326–335, Dec. 2020, doi: 10.1007/s12609-020-00389-6.
N. T. Ueno et al., “International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference,” J. Cancer, vol. 9, no. 8, pp. 1437–1447, 2018, doi: 10.7150/jca.23969.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Jurnal Sains dan Kesehatan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
